Krystal Biotech (KRYS)
(Delayed Data from NSDQ)
$181.47 USD
-0.56 (-0.31%)
Updated Oct 1, 2024 04:00 PM ET
After-Market: $181.25 -0.22 (-0.12%) 7:58 PM ET
1-Strong Buy of 5 1
F Value C Growth D Momentum F VGM
Income Statements
Fiscal Year end for Krystal Biotech, Inc falls in the month of December .
All items in Millions except EPS data.
12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 | |
---|---|---|---|---|---|
Sales | 51 | 0 | 0 | 0 | 0 |
Cost Of Goods | 3 | 0 | 0 | 0 | 0 |
Gross Profit | 48 | 0 | 0 | 0 | 0 |
Selling & Adminstrative & Depr. & Amort Expenses | 157 | 145 | 68 | 33 | 22 |
Income After Depreciation & Amortization | -110 | -145 | -68 | -33 | -22 |
Non-Operating Income | 123 | 5 | 0 | 1 | 3 |
Interest Expense | 0 | 0 | 1 | 0 | 0 |
Pretax Income | 13 | -140 | -70 | -32 | -19 |
Income Taxes | 2 | 0 | 0 | 0 | 0 |
Minority Interest | 0 | 0 | 0 | 0 | 0 |
Investment Gains/Losses | 0 | 0 | 0 | 0 | 0 |
Other Income/Charges | 0 | 0 | 0 | 0 | 0 |
Income From Cont. Operations | 11 | -140 | -70 | -32 | -19 |
Extras & Discontinued Operations | 0 | 0 | 0 | 0 | 0 |
Net Income (GAAP) | 11 | -140 | -70 | -32 | -19 |
Depreciation Footnote | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Income Before Depreciation & Amortization | -106 | -141 | -66 | -31 | -21 |
Depreciation & Amortization (Cash Flow) | 4 | 4 | 3 | 2 | 1 |
Income After Depreciation & Amortization | -110 | -145 | -68 | -33 | -22 |
Earnings Per Share Data | 12/31/23 | 12/31/22 | 12/31/21 | 12/31/20 | 12/31/19 |
---|---|---|---|---|---|
Average Shares | 27.75 | 25.49 | 22.20 | 18.79 | 15.90 |
Diluted EPS Before Non-Recurring Items | -2.76 | -4.51 | -3.13 | -1.71 | -1.20 |
Diluted Net EPS (GAAP) | 0.39 | -5.49 | -3.13 | -1.71 | -1.20 |
Fiscal Year end for Krystal Biotech, Inc falls in the month of December .
All items in Millions except EPS data.
9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 | |
---|---|---|---|---|---|
Sales | 70.28 | 45.25 | 42.14 | 8.56 | 0.00 |
Cost Of Goods | 6.01 | 2.42 | 2.87 | 0.22 | 0.00 |
Gross Profit | 64.27 | 42.83 | 39.27 | 8.33 | 0.00 |
SG&A, R&D, and Dept/Amort Expenses | 55.71 | 49.52 | 36.14 | 34.33 | 38.04 |
Income After SG&A, R&D, and Dept/Amort Expenses | 8.56 | -6.69 | 3.13 | -26.00 | -38.04 |
Non-Operating Income | 7.48 | 7.62 | 7.52 | 106.74 | 4.84 |
Interest Expense | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Pretax Income | 16.05 | 0.93 | 10.66 | 80.75 | -33.21 |
Income Taxes | 0.48 | 0.00 | 1.97 | 0.00 | 0.00 |
Minority Interest | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Investment Gains/Losses | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Other Income/Charges | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Income From Cont. Operations | 15.57 | 0.93 | 8.69 | 80.75 | -33.21 |
Extras & Discontinued Operations | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income (GAAP) | 15.57 | 0.93 | 8.69 | 80.75 | -33.21 |
Earnings Per Share Data | 9/30/24 | 6/30/24 | 3/31/24 | 12/31/23 | 9/30/23 |
---|---|---|---|---|---|
Average Shares | 29.64 | 29.29 | 28.82 | 28.89 | 26.66 |
Diluted EPS Before Non-Recurring Items | 0.86 | 0.03 | 0.30 | -0.67 | -1.25 |
Diluted Net EPS (GAAP) | 0.53 | 0.03 | 0.61 | 2.79 | -1.25 |